Mathematical Problems in Engineering

Research Article

A Proposal Mathematical Model for the Vaccine COVID-19 Distribution Network: A Case Study in Mexico

Table 2

Total confirmed doses by entity.
EntityVaccineGrand total
European UnionPfizer, AstraZeneca, Moderna, Novavax, Janssen, Sanofi, CureVac, and Valneva2,885,000,000
COVAXPfizer, AstraZeneca, Moderna, Novavax, Janssen, and Sanofi2,361,000,000
USAPfizer, AstraZeneca, Moderna, Novavax, Janssen, Sanofi, and Covaxin1,210,000,000
UKPfizer, AstraZeneca, Moderna, Novavax, Janssen, Sanofi, CureVac, and Valneva517,000,000
BrazilPfizer, AstraZeneca, Moderna, Janssen, Sinovac, Sputnik V, and Covaxin450,000,000
IndiaAstraZeneca, Novavax, Sputnik V, and Covaxin390,000,000
CanadaPfizer, AstraZeneca, Moderna, Novavax, Janssen, Sanofi, and Medicago381,000,000
JapanPfizer, AstraZeneca, and Moderna314,000,000
African UnionPfizer, Janssen, and Sputnik V270,000,000
IndonesiaPfizer, AstraZeneca, Novavax, Sinovac, Sinopharm, and CanSino255,500,000
TurkeyPfizer, Sinovac, and Sputnik V214,500,000
MexicoPfizer, AstraZeneca, Moderna, Novavax, Janssen, Sinovac, Sputnik V, CureVac, Sinopharm, and CanSino204,830,000